updates from adaura: continued dfs benefit with osimertinib vs. placebo
Published 1 year ago • 274 plays • Length 3:13Download video MP4
Download video MP3
Similar videos
-
1:08
adaura clinical trial update
-
1:42
adaura: the benefit of adjuvant osimertinib
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
1:37
dr. levy on the dfs benefit achieved with adjuvant osimertinib in egfr nsclc
-
4:17
nsclc trial updates at esmo 2022: adaura, destiny-lung02, kn189, kn407 & poseidon
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
11:37
asco23 - lba3: os analysis from the adaura trial of adjuvant osimertinib in resected egfr‐mutate...
-
4:24
reflections on the adaura study
-
5:54
key points from the adaura trial: osimertinib - targeted therapies in lung cancer 2023
-
2:21
treatment of egfr nsclc after progression
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
48:31
dr. sanjay popat, where the dust has settled with adjuvant osimertinib after adaura trial | btj-003
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
3:52
is adjuvant chemotherapy in egfr mutated nsclc still required?
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
4:46
5-year survival outcomes from the pacific trial